A Testing Campaign Intervention Consisting of Peer-Facilitated Engagement, Point-of-Care HCV RNA Testing, and Linkage to Nursing Support to Enhance Hepatitis C Treatment Uptake among People Who Inject Drugs: The ETHOS Engage Study.

Adult Antiviral Agents / therapeutic use Drug Users Female Hepacivirus / genetics Hepatitis C / diagnosis Humans Male Point-of-Care Systems RNA Substance Abuse, Intravenous / complications
Hepatitis C virus elimination Hepatitis C virus infection Hepatitis C virus treatment direct-acting antiviral era people who inject drugs

Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
16 07 2022
Historique:
received: 06 06 2022
revised: 08 07 2022
accepted: 14 07 2022
entrez: 27 7 2022
pubmed: 28 7 2022
medline: 29 7 2022
Statut: epublish

Résumé

This study evaluated HCV treatment initiation among people who inject drugs (PWID) following an intervention of campaign days involving peer connection, point-of-care HCV RNA testing, and linkage to nursing support. ETHOS Engage is an observational cohort study of PWID attending 25 drug treatment clinics and needle and syringe programs in Australia (May 2018-September 2019). Point-of-care results were provided to the nurse, facilitating confirmatory testing and treatment. The study aimed to evaluate treatment uptake and factors associated with treatment at 24 months post-enrolment. There were 317 people with current HCV infection and eligible for treatment (median age 43, 65% male, 15% homeless, 69% receiving opioid agonist treatment, 70% injected in last month). Overall, 15% (47/317), 27% (85/317), 38% (120/317), and 49% (155/317) of people with current HCV infection had initiated treatment at 3-, 6-, 12-, and 24-months following testing, respectively. Homelessness (adjusted hazard ratio (aHR): 0.40; 95% confidence interval: 0.23, 0.71) and incarceration in the past 12 months (vs. never, aHR:0.46; 0.28, 0.76) were associated with decreased treatment initiation in the 24 months post-enrolment. This testing campaign intervention facilitated HCV treatment uptake among PWID. Further interventions are needed to achieve HCV elimination among people experiencing homelessness or incarceration.

Identifiants

DOI: 10.3390/v14071555 PMID: 35891535 PMC: PMC9316739
pubmed: 35891535
pii: v14071555
doi: 10.3390/v14071555
pmc: PMC9316739
pii:
doi:

Substances chimiques

Antiviral Agents 0
RNA 63231-63-0

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

BMC Infect Dis. 2021 Sep 13;21(Suppl 2):874
pubmed: 34517819
BMC Infect Dis. 2019 Aug 8;19(1):703
pubmed: 31395019
Health Expect. 2022 Feb;25(1):48-60
pubmed: 34862710
BMC Public Health. 2020 Jul 20;20(1):1138
pubmed: 32689966
Hepatology. 2019 Jan;69(1):51-63
pubmed: 30019478
Addiction. 2019 Jan;114(1):150-166
pubmed: 30035835
J Hepatol. 2020 Nov;73(5):1170-1218
pubmed: 32956768
Lancet Gastroenterol Hepatol. 2022 May;7(5):426-445
pubmed: 35303490
Int J Drug Policy. 2018 Nov;61:23-30
pubmed: 30388566
Lancet Glob Health. 2021 Apr;9(4):e431-e445
pubmed: 33639097
Harm Reduct J. 2013 May 07;10:7
pubmed: 23651646
Clin Infect Dis. 2021 Dec 6;73(11):2037-2044
pubmed: 34107022
Int J Drug Policy. 2015 Oct;26(10):992-8
pubmed: 25697089
J Viral Hepat. 2020 Mar;27(3):281-293
pubmed: 31698545
Lancet HIV. 2017 Aug;4(8):e357-e374
pubmed: 28515014
Lancet Infect Dis. 2021 Jan;21(1):e11-e16
pubmed: 33007225
Drug Alcohol Depend. 2020 Jan 1;206:107705
pubmed: 31718924
Clin Infect Dis. 2021 Jul 1;73(1):e69-e78
pubmed: 32421194
Int J Drug Policy. 2017 Sep;47:34-46
pubmed: 28797498
J Viral Hepat. 2018 Jun;25(6):640-648
pubmed: 29274192
Int J Drug Policy. 2021 Sep;95:103261
pubmed: 33990057
Soc Sci Med. 2013 Apr;83:19-26
pubmed: 23465200
Liver Int. 2022 Feb;42(2):309-319
pubmed: 34767680
Drug Alcohol Depend. 2022 Jun 1;235:109438
pubmed: 35430521
J Hepatol. 2021 Feb;74(2):293-302
pubmed: 32931879
Alcohol Clin Exp Res. 1998 Nov;22(8):1842-9
pubmed: 9835306
Int J Drug Policy. 2017 Dec;50:111-115
pubmed: 28927831
Lancet Public Health. 2022 Feb;7(2):e136-e145
pubmed: 35012711
Int J Drug Policy. 2022 Jul;105:103706
pubmed: 35533635
PLoS One. 2018 Nov 30;13(11):e0207226
pubmed: 30500863
Int J Drug Policy. 2021 Oct;96:103424
pubmed: 34429222
BMC Med. 2017 May 3;15(1):92
pubmed: 28464883
Lancet Gastroenterol Hepatol. 2021 Jul;6(7):533-546
pubmed: 33965006
J Viral Hepat. 2019 Aug;26(8):969-979
pubmed: 30980785
Lancet. 2018 Jan 20;391(10117):241-250
pubmed: 29137869

Auteurs

Anna Conway (A)

The Kirby Institute, UNSW Sydney, Sydney, NSW 2052, Australia.
Centre for Social Research in Health, UNSW Sydney, Sydney, NSW 2052, Australia.
ORCID: 0000-0002-9082-9714

Heather Valerio (H)

The Kirby Institute, UNSW Sydney, Sydney, NSW 2052, Australia.

Maryam Alavi (M)

The Kirby Institute, UNSW Sydney, Sydney, NSW 2052, Australia.

David Silk (D)

The Kirby Institute, UNSW Sydney, Sydney, NSW 2052, Australia.

Carla Treloar (C)

Centre for Social Research in Health, UNSW Sydney, Sydney, NSW 2052, Australia.

Behzad Hajarizadeh (B)

The Kirby Institute, UNSW Sydney, Sydney, NSW 2052, Australia.
ORCID: 0000-0003-2212-2028

Alison D Marshall (AD)

The Kirby Institute, UNSW Sydney, Sydney, NSW 2052, Australia.
Centre for Social Research in Health, UNSW Sydney, Sydney, NSW 2052, Australia.

Marianne Martinello (M)

The Kirby Institute, UNSW Sydney, Sydney, NSW 2052, Australia.

Andrew Milat (A)

Centre for Epidemiology and Evidence, NSW Health, Sydney, NSW 2065, Australia.

Adrian Dunlop (A)

Hepatitis NSW, Surry Hills, NSW 2010, Australia.
Drug and Alcohol Clinical Services, Hunter New England Local Health District, Newcastle, NSW 2300, Australia.

Carolyn Murray (C)

Population Health Strategy & Performance, NSW Health, Sydney, NSW 2065, Australia.

Bianca Prain (B)

Population Health Strategy & Performance, NSW Health, Sydney, NSW 2065, Australia.

Charles Henderson (C)

NSW Users and AIDS Association, Surry Hills, NSW 2010, Australia.

Janaki Amin (J)

Department of Health Systems and Populations, Macquarie University, Sydney, NSW 2109, Australia.

Phillip Read (P)

Kirketon Road Centre, Sydney, NSW 2010, Australia.

Pip Marks (P)

The Kirby Institute, UNSW Sydney, Sydney, NSW 2052, Australia.

Louisa Degenhardt (L)

National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, NSW 2052, Australia.

Jeremy Hayllar (J)

Alcohol and Drug Service, Metro North Mental Health, Metro North Hospital and Health Service, Brisbane, QLD 4029, Australia.

David Reid (D)

Drug and Alcohol Service, Illawarra Shoalhaven Local Health District, Wollongong, NSW 2500, Australia.

Carla Gorton (C)

Cairns Sexual Health Service, Cairns, QLD 4870, Australia.

Thao Lam (T)

Drug Health, Western Sydney Local Health District, Sydney, NSW 2145, Australia.

Michael Christmass (M)

Next Step Community Alcohol and Drug Service, Perth, WA 6004, Australia.
National Drug Research Institute, Curtin University, Perth, WA 6102, Australia.

Alexandra Wade (A)

Mid North Coast Liver Clinic, Mid North Coast Local Health District, Coffs Harbour, NSW 2450, Australia.
Drug and Alcohol Services, Mid North Coast Local Health District, Coffs Harbour, NSW 2450, Australia.

Mark Montebello (M)

North Sydney Local Health District, Sydney, NSW 2077, Australia.
ORCID: 0000-0002-1776-3974

Gregory J Dore (GJ)

The Kirby Institute, UNSW Sydney, Sydney, NSW 2052, Australia.

Jason Grebely (J)

The Kirby Institute, UNSW Sydney, Sydney, NSW 2052, Australia.
ORCID: 0000-0002-1833-2017

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

Recherchemedicale.com › Personnes › Tranches d'âge › Adulte › A Testing Campaign Intervention Consisting of...
Recherchemedicale.com › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antiviraux › A Testing Campaign Intervention Consisting of...
Recherchemedicale.com › Personnes › Usagers de drogues › A Testing Campaign Intervention Consisting of...
Recherchemedicale.com › Virus › Virus à ARN › Virus à ARN à brin positif › Flaviviridae › Hepacivirus › A Testing Campaign Intervention Consisting of...
Recherchemedicale.com › Maladies de l'appareil digestif › Maladies du foie › Hépatite › Hépatites virales humaines › Hépatite C › A Testing Campaign Intervention Consisting of...
Recherchemedicale.com › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › A Testing Campaign Intervention Consisting of...
Recherchemedicale.com › Administration des services de santé › Gestion des soins aux patients › Systèmes automatisés lit malade › A Testing Campaign Intervention Consisting of...
Recherchemedicale.com › Acides nucléiques, nucléotides et nucléosides › Acides nucléiques › ARN › A Testing Campaign Intervention Consisting of...
Recherchemedicale.com › Troubles mentaux › Troubles liés à une substance › Toxicomanie intraveineuse › A Testing Campaign Intervention Consisting of...